Acharya A, Glurich I, Hetzel S, et al. - The association between oral health and systemic inflammation (COHESION) trial was performed to investigate the hypothesis that PlaqueHD, a plaque identifying toothpaste, reduces hs-CRP. This study included a total of 132 individuals with high sensitivity C-reactive protein (hs-CRP) between 2.0 and 10.0 milligrams per liter but randomized 112 between 0.5 and 10.0, of which 103 had baseline and follow up data and comprise the intention to treat sample. There were no significant differences between the PlaqueHD and the placebo group in the intention-to-treat analysis. A significant difference was found between the PlaqueHD and the placebo group in the pre-specified subgroup analysis. The data is compatible with those of a prior pilot trial which also implied benefits only in subjects with baseline elevations. The outcomes of this study demonstrated that future trials targeting reductions of hs-CRP levels should randomize individuals with baseline hs-CRP between 2.0 and 10.0 mg/L.